Literature DB >> 30239800

Pathological Relationship Between Adamantinomatous Craniopharyngioma and Adjacent Structures Based on QST Classification.

Yi Liu1, Song-Tao Qi1, Chao-Hu Wang1, Jun Pan1, Jun Fan1, Jun-Xiang Peng1, Xi'an Zhang1, Yun Bao1, Ya-Wei Liu1.   

Abstract

The aim of this study was to clarify pathological and anatomical relationships between adamantinomatous craniopharyngiomas (ACP) and their surrounding structures. We previously established a QST classification scheme based on the apparent anatomic origin of the tumors. According to this classification, 13 type Q tumors, 6 type S tumors, and 42 type T ACPs were analyzed. Type Q tumors, which are most likely to involve the pituitary gland, did not invade the area of contact with the adenohypophysis. Instead, tumor invasion was observed in areas where the tumor contacted the neurohypophysis. Type S tumors primarily involved the pituitary stalk; the arachnoid remained present between these tumors and normal structures. Type T tumors were located beneath the basal arachnoid membrane and outside the pia mater. The pia mater was disrupted and finger-like invasions were found in the neural layer of the third ventricle floor along the invasive front. Tumors were never observed to break through the ependymal layer of the third ventricle. The QST classification has important implications for understanding the growth pattern of tumors and can be used to guide surgical procedures.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30239800     DOI: 10.1093/jnen/nly083

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  8 in total

1.  Clinical impact of craniopharyngioma classification based on location origin: a multicenter retrospective study.

Authors:  Wenfu Hu; Binghui Qiu; Fen Mei; Jian Mao; Lizhi Zhou; Fan Liu; Jun Fan; Yi Liu; Ge Wen; Songtao Qi; Yun Bao; Jun Pan
Journal:  Ann Transl Med       Date:  2021-07

2.  Complications of Endoscopic Skull Base Surgery for Sellar and Parasellar Tumors in Pediatric Population; Neurosurgical Perspectives.

Authors:  Jeyul Yang; Yong Hwy Kim; Ji Hoon Phi; Seung-Ki Kim; Kyu-Chang Wang
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

3.  Non-Invasive Radiomics Approach Predict Invasiveness of Adamantinomatous Craniopharyngioma Before Surgery.

Authors:  Guofo Ma; Jie Kang; Ning Qiao; Bochao Zhang; Xuzhu Chen; Guilin Li; Zhixian Gao; Songbai Gui
Journal:  Front Oncol       Date:  2021-02-17       Impact factor: 6.244

Review 4.  Endocrine Disorder in Patients With Craniopharyngioma.

Authors:  Zihao Zhou; Sheng Zhang; Fangqi Hu
Journal:  Front Neurol       Date:  2021-12-02       Impact factor: 4.003

5.  Reinvestigating Tumor-Ventricle Relationship of Craniopharyngiomas With Predominantly Ventricular Involvement: An Endoscopic Endonasal Series Based on Histopathological Assessment.

Authors:  Jun Fan; Yi Liu; Chaohu Wang; Zhanpeng Feng; Jun Pan; Yuping Peng; Junxiang Peng; Yun Bao; Jing Nie; Binghui Qiu; Songtao Qi
Journal:  Front Oncol       Date:  2021-12-03       Impact factor: 6.244

6.  Extended Neuroendoscopic Endonasal Approach for Resection of Craniopharyngioma in Children.

Authors:  Danyang Wu; Ling Xu; Sungel Xie; Feiji Sun; Mingxiang Xie; Pei Wang; Shunwu Xiao
Journal:  Front Neurol       Date:  2022-01-31       Impact factor: 4.003

7.  Integrin α6 Indicates a Poor Prognosis of Craniopharyngioma through Bioinformatic Analysis and Experimental Validation.

Authors:  Yanfei Jia; Wentao Wu; Youchao Xiao; Kefan Cai; Songbai Gui; Qiang Li; Tian Li
Journal:  J Oncol       Date:  2022-10-11       Impact factor: 4.501

8.  Development and Validation of Predicting Nomograms for Craniopharyngioma: A Retrospective, Multiple-Center, Cohort Study.

Authors:  Dingkang Xu; Qingjie Wei; Zhe Li; Yan Hu; Peizhu Hu; Shengqi Zhao; Dengpan Song; Shixiong Lei; Mingchu Zhang; Qiang Gao; Longxiao Zhang; Fangbo Lin; Yuchao Zuo; Xianzhi Liu; Mengzhao Feng; Chunxiao Ma; Fuyou Guo
Journal:  Front Oncol       Date:  2021-07-12       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.